# Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis

> **NCT04132960** · PHASE2 · COMPLETED · sponsor: **UNICANCER** · enrollment: 186 (actual)

## Conditions studied

- Breast Tumors

## Interventions

- **DRUG:** DS-8201a

## Key facts

- **NCT ID:** NCT04132960
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-21
- **Primary completion:** 2021-10-29
- **Final completion:** 2024-12-26
- **Target enrollment:** 186 (ACTUAL)
- **Last updated:** 2025-06-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04132960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04132960, "Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT04132960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*